Compare Nvidia Corp (NVDA) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Nvidia Corp trades at $229.77 (market cap $5.57T), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Nvidia Corp is far larger — about 94.8× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| NVDA | TAK | |
|---|---|---|
Market Cap | $5.57T | $58.74B |
Volume | 117,720,595 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $239.27 | $19.05 |
52-Week Low | $165.17 | $13.23 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $5.54T | $86.65B |
Dividend Yield | 0.43% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $229.25, down 3.42% over the past day amid a broader tech sell-off. The stock maintains a bullish technical signal with strong support near $228 and resistance at $235. Fundamentally, the company reported record revenue of $130.50B in 2025, with net income surging to $72.88B, reflecting a 55.84% profit margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.22 surpassing the $2.09 estimate. Analyst sentiment remains overwhelmingly positive, with a consensus price target of $339.17 implying significant upside.
NVDA's outlook is supported by robust AI chip demand and accelerating revenue growth, projected to reach $303.0B in 2026. However, risks include heightened competition, potential peak AI spending, and geopolitical tensions affecting market sentiment. The stock presents a compelling growth opportunity but requires monitoring of execution risks and macroeconomic headwinds.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
